Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ845846-0,94
KB8428431,26
PKN64,9264,941,91
Msft420,04420,12-0,36
Nokia3,29353,2975-1,42
IBM191,16191,280,34
Mercedes-Benz Group AG7474,020,65
PFE27,927,910,27
28.03.2024 14:42:56
Indexy online
AD Index online
select
AD Index online
 

  • 28.03.2024 14:37:28
Sangamo Biosci (SGMO.O, NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
0,63 1,04 0,01 18 863
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 28.03.2024
Popis společnosti
Obecné informace
Název společnostiSangamo Therapeutics Inc
TickerSGMO
Kmenové akcie:Ordinary Shares
RICSGMO.O
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 405
Akcie v oběhu k 08.03.2024 178 906 350
MěnaUSD
Kontaktní informace
Ulice501 Canal Blvd.
MěstoRICHMOND
PSČ94084
ZeměUnited States
Kontatní osobaLouise Wilkie
Funkce kontaktní osobyInvestor Relations
Telefon15 109 706 000
Fax13026555049
Kontatní telefon16 282 527 840

Business Summary: Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Sangamo Therapeutics Inc revenues increased 58% to $176.2M. Net loss increased 34% to $257.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.25 to -$1.48.
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Research and Development in Biotechnology
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research



  • Poslední aktualizace: 28.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorAlexander Macrae6014.06.201601.06.2016
Chief Financial Officer, Senior Vice PresidentPrathyusha Duraibabu4401.06.202114.06.2019
Senior Vice President, General Counsel, Corporate SecretaryScott Willoughby48
Senior Vice President, Chief Development OfficerNathalie Dubois- Stringfellow6119.08.202219.08.2022
Chief Medical OfficerLisa Rojkjaer5716.05.202316.05.2023